To date there are no approved therapies to target TGF-β1 for the treatment of pulmonary fibrosis, so furthering our understanding of the profibrotic effects of TGF-β1 may lead to an effective therapy for pulmonary fibrosis. The gene discussed is TGFB1; the disease is pulmonary fibrosis.